A Narrative Review of Ocular Surface Disease Related to Anti-Glaucomatous Medications
Topical anti-glaucomatous medications are still the most important measure to lower intraocular pressure. Large number of studies have confirmed that long-term use of anti-glaucomatous eye drops, especially containing benzalkonium chloride, a preservative, can cause or aggravate ocular surface injur...
Gespeichert in:
| Veröffentlicht in: | Ophthalmology and Therapy 2022-10, Vol.11 (5), p.1681-1704 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1704 |
|---|---|
| container_issue | 5 |
| container_start_page | 1681 |
| container_title | Ophthalmology and Therapy |
| container_volume | 11 |
| creator | Zhou, Xiaoyu Zhang, Xinyue Zhou, Dengming zhao, Yang Duan, Xuanchu |
| description | Topical anti-glaucomatous medications are still the most important measure to lower intraocular pressure. Large number of studies have confirmed that long-term use of anti-glaucomatous eye drops, especially containing benzalkonium chloride, a preservative, can cause or aggravate ocular surface injury. Ocular surface diseases damage the ocular microenvironmental health status, reduce the patients’ compliance with the treatment, and finally affect the treatment result. Therefore, the ocular surface management of patients with glaucoma is very important. This includes the selection of drugs that are better tolerated according to individual conditions, preservative-free formulations, drugs that protect against ocular surface disease, or selecting surgery and laser treatment, to prevent the damage to the ocular surface by topical anti-glaucomatous drugs. |
| doi_str_mv | 10.1007/s40123-022-00557-0 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9437175</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A715924234</galeid><sourcerecordid>A715924234</sourcerecordid><originalsourceid>FETCH-LOGICAL-c490t-e8a8dec43f77d33b1fe5ada05927644f1c8fa997bc6426941b0ab1e96c73ae053</originalsourceid><addsrcrecordid>eNp9kU9v1DAQxSMEolXpF-DkI5cU_43jC9KqQEEqVAJ6tibOeHGV2MVOFvHt8ZIVEhfkw1ie33vyzGual4xeMUr16yIp46KlnLeUKqVb-qQ558yItlO8f3q691yqs-aylAdKK98rI-Xz5kzUKrquP2_ud-Qz5AxLOCD5goeAP0ny5M6tE2Tydc0eHJK3oSCUIzDBgiNZEtnFJbQ3E6wuzbCktZBPOAZXjVIsL5pnHqaCl6d60dy_f_ft-kN7e3fz8Xp32zpp6NJiD_2ITgqv9SjEwDwqGIEqw3UnpWeu92CMHlwneWckGygMDE3ntACkSlw0bzbfx3WYcXQYlwyTfcxhhvzLJgj2304M3-0-HWwdXzN9NHh1Msjpx4plsXMoDqcJItaZLNeUCqaMEhW92tA9TGhD9Kk6unpGnINLEX2o7ztdaS65kFXAN4HLqZSM_u-_GLXHDO2Woa0Z2j8ZWlpFYhOVCsc9ZvuQ1hzrEv-n-g1K153g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2700315953</pqid></control><display><type>article</type><title>A Narrative Review of Ocular Surface Disease Related to Anti-Glaucomatous Medications</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Springer Nature OA/Free Journals</source><creator>Zhou, Xiaoyu ; Zhang, Xinyue ; Zhou, Dengming ; zhao, Yang ; Duan, Xuanchu</creator><creatorcontrib>Zhou, Xiaoyu ; Zhang, Xinyue ; Zhou, Dengming ; zhao, Yang ; Duan, Xuanchu</creatorcontrib><description>Topical anti-glaucomatous medications are still the most important measure to lower intraocular pressure. Large number of studies have confirmed that long-term use of anti-glaucomatous eye drops, especially containing benzalkonium chloride, a preservative, can cause or aggravate ocular surface injury. Ocular surface diseases damage the ocular microenvironmental health status, reduce the patients’ compliance with the treatment, and finally affect the treatment result. Therefore, the ocular surface management of patients with glaucoma is very important. This includes the selection of drugs that are better tolerated according to individual conditions, preservative-free formulations, drugs that protect against ocular surface disease, or selecting surgery and laser treatment, to prevent the damage to the ocular surface by topical anti-glaucomatous drugs.</description><identifier>ISSN: 2193-8245</identifier><identifier>EISSN: 2193-6528</identifier><identifier>DOI: 10.1007/s40123-022-00557-0</identifier><identifier>PMID: 35943668</identifier><language>eng</language><publisher>Cheshire: Springer Healthcare</publisher><subject>Complications and side effects ; Corneal diseases ; Drug therapy ; Glaucoma ; Internal Medicine ; Medicine ; Medicine & Public Health ; Ophthalmic drugs ; Ophthalmology ; Review ; Risk factors</subject><ispartof>Ophthalmology and Therapy, 2022-10, Vol.11 (5), p.1681-1704</ispartof><rights>The Author(s) 2022</rights><rights>COPYRIGHT 2022 Springer</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c490t-e8a8dec43f77d33b1fe5ada05927644f1c8fa997bc6426941b0ab1e96c73ae053</citedby><cites>FETCH-LOGICAL-c490t-e8a8dec43f77d33b1fe5ada05927644f1c8fa997bc6426941b0ab1e96c73ae053</cites><orcidid>0000-0002-3148-1703</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437175/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437175/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,865,886,27929,27930,41125,42194,51581,53796,53798</link.rule.ids></links><search><creatorcontrib>Zhou, Xiaoyu</creatorcontrib><creatorcontrib>Zhang, Xinyue</creatorcontrib><creatorcontrib>Zhou, Dengming</creatorcontrib><creatorcontrib>zhao, Yang</creatorcontrib><creatorcontrib>Duan, Xuanchu</creatorcontrib><title>A Narrative Review of Ocular Surface Disease Related to Anti-Glaucomatous Medications</title><title>Ophthalmology and Therapy</title><addtitle>Ophthalmol Ther</addtitle><description>Topical anti-glaucomatous medications are still the most important measure to lower intraocular pressure. Large number of studies have confirmed that long-term use of anti-glaucomatous eye drops, especially containing benzalkonium chloride, a preservative, can cause or aggravate ocular surface injury. Ocular surface diseases damage the ocular microenvironmental health status, reduce the patients’ compliance with the treatment, and finally affect the treatment result. Therefore, the ocular surface management of patients with glaucoma is very important. This includes the selection of drugs that are better tolerated according to individual conditions, preservative-free formulations, drugs that protect against ocular surface disease, or selecting surgery and laser treatment, to prevent the damage to the ocular surface by topical anti-glaucomatous drugs.</description><subject>Complications and side effects</subject><subject>Corneal diseases</subject><subject>Drug therapy</subject><subject>Glaucoma</subject><subject>Internal Medicine</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Ophthalmic drugs</subject><subject>Ophthalmology</subject><subject>Review</subject><subject>Risk factors</subject><issn>2193-8245</issn><issn>2193-6528</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><recordid>eNp9kU9v1DAQxSMEolXpF-DkI5cU_43jC9KqQEEqVAJ6tibOeHGV2MVOFvHt8ZIVEhfkw1ie33vyzGual4xeMUr16yIp46KlnLeUKqVb-qQ558yItlO8f3q691yqs-aylAdKK98rI-Xz5kzUKrquP2_ud-Qz5AxLOCD5goeAP0ny5M6tE2Tydc0eHJK3oSCUIzDBgiNZEtnFJbQ3E6wuzbCktZBPOAZXjVIsL5pnHqaCl6d60dy_f_ft-kN7e3fz8Xp32zpp6NJiD_2ITgqv9SjEwDwqGIEqw3UnpWeu92CMHlwneWckGygMDE3ntACkSlw0bzbfx3WYcXQYlwyTfcxhhvzLJgj2304M3-0-HWwdXzN9NHh1Msjpx4plsXMoDqcJItaZLNeUCqaMEhW92tA9TGhD9Kk6unpGnINLEX2o7ztdaS65kFXAN4HLqZSM_u-_GLXHDO2Woa0Z2j8ZWlpFYhOVCsc9ZvuQ1hzrEv-n-g1K153g</recordid><startdate>20221001</startdate><enddate>20221001</enddate><creator>Zhou, Xiaoyu</creator><creator>Zhang, Xinyue</creator><creator>Zhou, Dengming</creator><creator>zhao, Yang</creator><creator>Duan, Xuanchu</creator><general>Springer Healthcare</general><general>Springer</general><scope>C6C</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IAO</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3148-1703</orcidid></search><sort><creationdate>20221001</creationdate><title>A Narrative Review of Ocular Surface Disease Related to Anti-Glaucomatous Medications</title><author>Zhou, Xiaoyu ; Zhang, Xinyue ; Zhou, Dengming ; zhao, Yang ; Duan, Xuanchu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c490t-e8a8dec43f77d33b1fe5ada05927644f1c8fa997bc6426941b0ab1e96c73ae053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Complications and side effects</topic><topic>Corneal diseases</topic><topic>Drug therapy</topic><topic>Glaucoma</topic><topic>Internal Medicine</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Ophthalmic drugs</topic><topic>Ophthalmology</topic><topic>Review</topic><topic>Risk factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhou, Xiaoyu</creatorcontrib><creatorcontrib>Zhang, Xinyue</creatorcontrib><creatorcontrib>Zhou, Dengming</creatorcontrib><creatorcontrib>zhao, Yang</creatorcontrib><creatorcontrib>Duan, Xuanchu</creatorcontrib><collection>Springer Nature OA/Free Journals</collection><collection>CrossRef</collection><collection>Gale Academic OneFile</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Ophthalmology and Therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhou, Xiaoyu</au><au>Zhang, Xinyue</au><au>Zhou, Dengming</au><au>zhao, Yang</au><au>Duan, Xuanchu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Narrative Review of Ocular Surface Disease Related to Anti-Glaucomatous Medications</atitle><jtitle>Ophthalmology and Therapy</jtitle><stitle>Ophthalmol Ther</stitle><date>2022-10-01</date><risdate>2022</risdate><volume>11</volume><issue>5</issue><spage>1681</spage><epage>1704</epage><pages>1681-1704</pages><issn>2193-8245</issn><eissn>2193-6528</eissn><abstract>Topical anti-glaucomatous medications are still the most important measure to lower intraocular pressure. Large number of studies have confirmed that long-term use of anti-glaucomatous eye drops, especially containing benzalkonium chloride, a preservative, can cause or aggravate ocular surface injury. Ocular surface diseases damage the ocular microenvironmental health status, reduce the patients’ compliance with the treatment, and finally affect the treatment result. Therefore, the ocular surface management of patients with glaucoma is very important. This includes the selection of drugs that are better tolerated according to individual conditions, preservative-free formulations, drugs that protect against ocular surface disease, or selecting surgery and laser treatment, to prevent the damage to the ocular surface by topical anti-glaucomatous drugs.</abstract><cop>Cheshire</cop><pub>Springer Healthcare</pub><pmid>35943668</pmid><doi>10.1007/s40123-022-00557-0</doi><tpages>24</tpages><orcidid>https://orcid.org/0000-0002-3148-1703</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2193-8245 |
| ispartof | Ophthalmology and Therapy, 2022-10, Vol.11 (5), p.1681-1704 |
| issn | 2193-8245 2193-6528 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9437175 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Springer Nature OA/Free Journals |
| subjects | Complications and side effects Corneal diseases Drug therapy Glaucoma Internal Medicine Medicine Medicine & Public Health Ophthalmic drugs Ophthalmology Review Risk factors |
| title | A Narrative Review of Ocular Surface Disease Related to Anti-Glaucomatous Medications |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T14%3A58%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Narrative%20Review%20of%20Ocular%20Surface%20Disease%20Related%20to%20Anti-Glaucomatous%20Medications&rft.jtitle=Ophthalmology%20and%20Therapy&rft.au=Zhou,%20Xiaoyu&rft.date=2022-10-01&rft.volume=11&rft.issue=5&rft.spage=1681&rft.epage=1704&rft.pages=1681-1704&rft.issn=2193-8245&rft.eissn=2193-6528&rft_id=info:doi/10.1007/s40123-022-00557-0&rft_dat=%3Cgale_pubme%3EA715924234%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2700315953&rft_id=info:pmid/35943668&rft_galeid=A715924234&rfr_iscdi=true |